Takeshi Morimoto
12
1
2
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.3%
1 terminated/withdrawn out of 12 trials
90.0%
+3.5% vs industry average
100%
12 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
GOREISAN for Heart Failure (GOREISAN-HF) Trial
Role: lead
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
Role: lead
Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
Role: lead
Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease
Role: lead
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
Role: lead
Carvedilol Post-intervention Long-term Administration in Large-scale Trial
Role: lead
Evaluation of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention Trial
Role: lead
Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan
Role: lead
Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound
Role: lead
Short and Optimal Duration of Dual Antiplatelet Therapy Study
Role: lead
NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial
Role: lead
Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial
Role: lead
All 12 trials loaded